[Correspondence] Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW – Authors' reply

We thank Akhil Santhosh and Nihanthy D Sreenath and Liting Zhang and colleagues for their interest in our trial. The CheckMate 9DW trial showed clinically significant overall survival benefit for nivolumab plus ipilimumab versus lenvatinib or sorafenib (median overall survival, 23·7 vs 20·6 months; hazard ratio 0·79) in unresectable hepatocellular carcinoma.1 We concur with Akhil Santhosh and Nihanthy Sreenath that further investigation of biomarkers could refine patient selection, given that some patients with hepatocellular carcinoma do not benefit from currently available therapies.